Prof Harris speaks at the Highlighting Welsh Cancer Research Conference about the use of blood-based tumour markers, as reviewed by the Early Cancer Detection Consortium.

Highlighting circulating tumour cells (CTCs) and DNA methylation as assays currently available, he considers the shortfalls in specificity and clinical adoption of biomarkers, and introduces Grail as an upcoming assay aiming for better outcomes.

Prof Harris also discusses Raman spectroscopy, by which plasma may be assessed through laser scattering to determine the presence of CTCs.